DGAP-News: Eckert&Ziegler: Overproportional Revenue Growth
(firmenpresse) - DGAP-News: Eckert&Ziegler Strahlen- und Medizintechnik AG / Key
word(s): Final Results
Eckert&Ziegler: Overproportional Revenue Growth
30.03.2012 / 07:50
---------------------------------------------------------------------
Berlin, March 30, 2012. The Berlin company, Eckert&Ziegler Strahlen- und
Medizintechnik AG (ISIN DE0005659700), a specialist for isotope
applications in medicine, science and industry, was able significantly to
increase its sales and revenues in the just ended financial year 2011. With
the revenue key figures, the company gained overall in double digits: the
EBITDA grew by 15% to EUR 30.4 million, the EBIT by 38% to EUR 22.9 million
and the income after taxes and minority interests by 11%, to EUR 10.4
million. This corresponds to earnings per share of EUR 1.98. Sales grew
organically overall by 5% to EUR 116.2 million.
Due to the jump in earnings, the operative cash flow of the Group increased
by a good third to over EUR 20.2 million (previous year: EUR 15.0 million).
The net liquidity, or the surplus of the means of payment above the loan
debts, grew by EUR 6.9 million to EUR 14.3 million.
The absolutely strongest growth area is again in the Isotope Products
segment, in which the sales grew by EUR 3.8 million to EUR 54.6 million.
This area profited from a robust demand for measurement technology
components. Relatively strongest, by 13%, or EUR 3.0 million, was the
growth in sales of radiopharmaceuticals. Primarily with contrast medium for
cancer diagnosis, the Radiopharma segment reached a new annual record
turnover of EUR 25.6 million. In the Radiation Therapy segment, the sales
fell according to expectations by EUR 1.7 million to EUR 30.4 million,
since turnover of past years from a system sale could not be repeated. In
the Environmental Services segment, sales fell slightly by 2%, to EUR 5.5
million.
The Executive Board and the Supervisory Board will recommend a dividend of
EUR 0.60 per dividend-entitled share (previous year: EUR 0.60) at the
Annual General Meeting on May 24, 2012.
With some 600 employees, the Eckert&Ziegler Group is one of the world's
largest providers of isotope-technical components for radiation therapy and
nuclear medicine.
If you have any questions, please contact:
Eckert&Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle(at)ezag.de, www.ezag.de
End of Corporate News
---------------------------------------------------------------------
30.03.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Eckert&Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: karolin.riehle(at)ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, Düsseldorf, Hamburg, München
End of News DGAP News-Service
---------------------------------------------------------------------
163138 30.03.2012
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 30.03.2012 - 07:50 Uhr
Sprache: Deutsch
News-ID 130230
Anzahl Zeichen: 6455
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 266 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Eckert&Ziegler: Overproportional Revenue Growth"
steht unter der journalistisch-redaktionellen Verantwortung von
Eckert&Ziegler Strahlen- und Medizintechnik AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
